Literature DB >> 7784019

Mutational analysis of the estrogen-receptor gene in endometrial carcinoma.

M F Kohler1, A Berkholz, J I Risinger, A Elbendary, J Boyd, A Berchuck.   

Abstract

OBJECTIVE: To determine whether mutation in the DNA of the estrogen-receptor gene occurs in endometrial cancer.
METHODS: Polymerase chain reaction amplification and single-stranded conformation polymorphism analysis of the entire coding region (exons 1-8) of the human estrogen-receptor gene, as well as an untranslated region (exon I*) in the gene, were performed on genomic DNA extracted from 56 snap-frozen endometrial cancers. All cancers demonstrating mobility shifts on single-stranded conformation polymorphism suggestive of DNA sequence alteration were subjected to definitive DNA sequencing of the relevant portion of the estrogen-receptor gene.
RESULTS: In addition to detecting a frequent, previously described polymorphism in exon 1, single-stranded conformation polymorphism analysis of the 56 endometrial cancers identified seven cancers with mobility shifts. Three cancers shifted in exon 3, one cancer each shifted in exons 4 and 7, and two shifted in exon 8. Deoxyribonucleic acid sequencing revealed sequence alterations in all seven cases demonstrating mobility shifts. In six of these seven cases, these alterations were consistent with infrequent silent polymorphisms; in the seventh cancer, the sequence alteration proved to be a somatic missense mutation at codon 537 in the region of the estrogen-receptor gene encoding the hormone-binding domain of the receptor protein.
CONCLUSION: The infrequent DNA mutation in the estrogen-receptor gene is unlikely to account for the variation in estrogen-receptor expression observed in endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784019     DOI: 10.1016/0029-7844(95)00113-6

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Authors:  Renjini Ambika Padmanabhan; Lini Nirmala; Megha Murali; Malini Laloraya
Journal:  Mol Endocrinol       Date:  2011-06-23

Review 2.  Estrogen receptor variants.

Authors:  T A Hopp; S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

3.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

Review 4.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

5.  Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.

Authors:  John I Risinger; Jay Allard; Uma Chandran; Roger Day; Gadisetti V R Chandramouli; Caela Miller; Christopher Zahn; Julie Oliver; Tracy Litzi; Charlotte Marcus; Elizabeth Dubil; Kevin Byrd; Yovanni Cassablanca; Michael Becich; Andrew Berchuck; Kathleen M Darcy; Chad A Hamilton; Thomas P Conrads; G Larry Maxwell
Journal:  Front Oncol       Date:  2013-06-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.